{
  "first_published_at": "2012-07-27", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON175429", 
  "title": "Dabigatran (Pradaxa▼): risk of serious haemorrhage – contraindications clarified and reminder to monitor renal function", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\", \"haematology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\", \"Haematology\"]}", 
  "_document_number": 108, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology", 
    "haematology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Dabigatran (Pradaxa&#9660;): risk of serious haemorrhage &#8211; contraindications clarified and reminder to monitor renal function</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: July 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Because of the risk of haemorrhage, dabigatran is contraindicated in a range of clinical conditions where the patient is at significant risk of major bleeding (listed in the main article). Dabigatran is also now contraindicated with dronedarone, and with the use of other anticoagulant agents, except when switching therapy to or from dabigatran, or with the use of unfractionated heparin for maintenance of venous or arterial catheter patency.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Because of the risk of haemorrhage, dabigatran is contraindicated in a range of clinical conditions where the patient is at significant risk of major bleeding (listed in the main article). Dabigatran is also now contraindicated with dronedarone, and with the use of other anticoagulant agents, except when switching therapy to or from dabigatran, or with the use of unfractionated heparin for maintenance of venous or arterial catheter patency.<br>\n<br>\nIn addition, as exposure to dabigatran is substantially increased in patients with renal insufficiency, renal function should be assessed in all patients before starting dabigatran and at least once a year in patients older than 75 years or those with a suspected decline in renal function.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Dabigatran (Pradaxa&#9660;) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation. It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip replacement surgery or total knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day).</p>\n\n<p>Haemorrhage is a common adverse reaction with dabigatran. A review of world-wide data on the risk of bleeding with dabigatran, including results from clinical trials (eg, the <a target=\"_blank\" href=\"www.ncbi.nlm.nih.gov/pubmed/22700854\">phase III RELY study </a>) and post-marketing surveillance, has resulted in further information and clearer advice &#160;on how best to minimise the risk of bleeding:</p>\n\n<div class=\"dull_highlight\">\n<h3>Updated advice on contraindications and warnings:</h3>\n\n<ul>\n<li>Dabigatran is contraindicated in clinical conditions associated with a significant risk of bleeding, such as: \n\n<ul>\n<li>current or recent gastrointestinal ulceration</li>\n\n<li>malignant neoplasms</li>\n\n<li>recent brain or spinal injury</li>\n\n<li>recent brain, spinal or ophthalmic surgery</li>\n\n<li>recent intracranial haemorrhage</li>\n\n<li>oesophageal varices</li>\n\n<li>arteriovenous malformations</li>\n\n<li>vascular aneurysms</li>\n\n<li>major intraspinal or intracerebral vascular abnormalities</li>\n</ul>\n</li>\n\n<li>The benefits and risks of starting dabigatran should also be considered carefully for patients who may have other conditions that put them at an increased risk of major bleeding (but in whom treatment with dabigatran is not contraindicated)</li>\n\n<li>Use of dabigatran is contraindicated with dronedarone, and with other anticoagulants, except when switching treatment to or from dabigatran, or with the use of unfractionated heparin for maintenance of venous or arterial catheter patency</li>\n\n<li>Concomitant use of antiplatelet agents increases the risk of major bleeding with dabigatran approximately two-fold, therefore a careful benefit-risk assessment should be made prior to initiation of treatment</li>\n</ul>\n\n<h3>Advice on switching treatment to and from dabigatran</h3>\n\n<ul>\n<li>When switching to dabigatran, the first dose of dabigatran should be given 0-2 hours prior to the time that the next dose of the alternate medicine is due, or at the time that continuous alternate treatment is discontinued</li>\n\n<li>When switching from dabigatran to parenteral anticoagulants, an interval of 12-24 hours (dependent upon treatment indication) is recommended between treatments</li>\n\n<li>When switching from dabigatran to warfarin in patients with atrial fibrillation, the starting time of warfarin should be adjusted according to creatinine clearance (CrCL): CrCL &#8805;50 ml/min, start warfarin 3 days before discontinuing dabigatran CrCL &#8805;30 - &#60;50 ml/min, start warfarin 2 days before discontinuing dabigatran</li>\n\n<li>For patients switching from warfarin to dabigatran, warfarin should be stopped and dabigatran can be given as soon as the INR is &#60;2.0.</li>\n</ul>\n\n<p>Product information will be updated with the new advice.</p>\n\n<h3>Reminder: importance of renal function monitoring</h3>\n\n<ul>\n<li>We previously advised on the importance of renal function monitoring in patients who receive dabigatran, as systemic exposure to dabigatran is substantially increased in patients with renal insufficiency (see <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137771\">December 2011 Drug Safety Update</a>)</li>\n</ul>\n\n<ul>\n<li>Renal function should be assessed in all patients before starting dabigatran and at least once a year in patients older than 75 years or those with a suspected decline in renal function. Dabigatran is contraindicated in patients with severe renal impairment (creatinine clearance &#60;30 mL/min)</li>\n</ul>\n\n<h3>Additional advice and information for healthcare professionals:</h3>\n\n<ul>\n<li>There is no specific antidote to dabigatran and excessive anticoagulation may require interruption of treatment</li>\n\n<li>In the event of haemorrhagic complications, dabigatran must be discontinued and the source of the bleeding investigated. Adequate diuresis must be maintained, and surgical haemostasis and blood volume replacement should be undertaken at the clinicians&#8217;s discretion<br />\n</li>\n\n<li>Additional measures may be considered in the treatment of serious haemorrhage, including: activated prothrombin complex concentrates, recombinant factor VIIa, or concentrates of coagulation factors II, IX and X, and platelet concentrates where appropriate. Coagulation tests may become unreliable following administration of reversing agents and measurements may remain elevated despite administration. Caution must be exercised when interpreting these results.<br />\n</li>\n</ul>\n</div>\n\n<p>A full list of contraindications and warnings, together with updated product information for dabigatran, can be found in the individual Summaries of Product Characteristics (see the <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&#38;mid=WC0b01ac058001d124\">EMA website</a>)</p>\n\n<h4>Further information:</h4>\n\n<p><a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&#38;mid=WC0b01ac058001d124] and to http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000829/WC500130142.pdf\">Information on dabigatran from the European Medicines Agency</a></p>\n\n<p>BNF section 2.8.2 <a target=\"_blank\" href=\"www.medicinescomplete.com/mc/bnf/current/2791.htm\">Oral anticoagulants</a></p>\n\n<p><em>Article citation: Drug Safety Update July 2012, vol 5 issue 12: A1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Dabigatran (Pradaxa&#9660;) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation. It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip replacement surgery or total knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day).</p>\n\n<p>Haemorrhage is a common adverse reaction with dabigatran. A review of world-wide data on the risk of bleeding with dabigatran, including results from clinical trials (eg, the <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.ncbi.nlm.nih.gov/pubmed/22700854\">phase III RELY study</a>) and post-marketing surveillance, has resulted in further information and clearer advice &#160;on how best to minimise the risk of bleeding:</p>\n\n<div class=\"dull_highlight\">\n<h3>Updated advice on contraindications and warnings:</h3>\n\n<ul>\n<li>Dabigatran is contraindicated in clinical conditions associated with a significant risk of bleeding, such as: \n\n<ul>\n<li>current or recent gastrointestinal ulceration</li>\n\n<li>malignant neoplasms</li>\n\n<li>recent brain or spinal injury</li>\n\n<li>recent brain, spinal or ophthalmic surgery</li>\n\n<li>recent intracranial haemorrhage</li>\n\n<li>oesophageal varices</li>\n\n<li>arteriovenous malformations</li>\n\n<li>vascular aneurysms</li>\n\n<li>major intraspinal or intracerebral vascular abnormalities</li>\n</ul>\n</li>\n\n<li>The benefits and risks of starting dabigatran should also be considered carefully for patients who may have other conditions that put them at an increased risk of major bleeding (but in whom treatment with dabigatran is not contraindicated)</li>\n\n<li>Use of dabigatran is contraindicated with dronedarone, and with other anticoagulants, except when switching treatment to or from dabigatran, or with the use of unfractionated heparin for maintenance of venous or arterial catheter patency</li>\n\n<li>Concomitant use of antiplatelet agents increases the risk of major bleeding with dabigatran approximately two-fold, therefore a careful benefit-risk assessment should be made prior to initiation of treatment</li>\n</ul>\n\n<h3>Advice on switching treatment to and from dabigatran</h3>\n\n<ul>\n<li>When switching to dabigatran, the first dose of dabigatran should be given 0-2 hours prior to the time that the next dose of the alternate medicine is due, or at the time that continuous alternate treatment is discontinued</li>\n\n<li>When switching from dabigatran to parenteral anticoagulants, an interval of 12-24 hours (dependent upon treatment indication) is recommended between treatments</li>\n\n<li>When switching from dabigatran to warfarin in patients with atrial fibrillation, the starting time of warfarin should be adjusted according to creatinine clearance (CrCL): CrCL &#8805;50 ml/min, start warfarin 3 days before discontinuing dabigatran CrCL &#8805;30 - &lt;50 ml/min, start warfarin 2 days before discontinuing dabigatran</li>\n\n<li>For patients switching from warfarin to dabigatran, warfarin should be stopped and dabigatran can be given as soon as the INR is &lt;2.0.</li>\n</ul>\n\n<p>Product information will be updated with the new advice.</p>\n\n<h3>Reminder: importance of renal function monitoring</h3>\n\n<ul>\n<li>We previously advised on the importance of renal function monitoring in patients who receive dabigatran, as systemic exposure to dabigatran is substantially increased in patients with renal insufficiency (see <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137771\">December 2011 Drug Safety Update</a>)</li>\n</ul>\n\n<ul>\n<li>Renal function should be assessed in all patients before starting dabigatran and at least once a year in patients older than 75 years or those with a suspected decline in renal function. Dabigatran is contraindicated in patients with severe renal impairment (creatinine clearance &lt;30 mL/min)</li>\n</ul>\n\n<h3>Additional advice and information for healthcare professionals:</h3>\n\n<ul>\n<li>There is no specific antidote to dabigatran and excessive anticoagulation may require interruption of treatment</li>\n\n<li>In the event of haemorrhagic complications, dabigatran must be discontinued and the source of the bleeding investigated. Adequate diuresis must be maintained, and surgical haemostasis and blood volume replacement should be undertaken at the clinicians&#8217;s discretion<br>\n</li>\n\n<li>Additional measures may be considered in the treatment of serious haemorrhage, including: activated prothrombin complex concentrates, recombinant factor VIIa, or concentrates of coagulation factors II, IX and X, and platelet concentrates where appropriate. Coagulation tests may become unreliable following administration of reversing agents and measurements may remain elevated despite administration. Caution must be exercised when interpreting these results.<br>\n</li>\n</ul>\n</div>\n\n<p>A full list of contraindications and warnings, together with updated product information for dabigatran, can be found in the individual Summaries of Product Characteristics (see the <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&amp;mid=WC0b01ac058001d124\">EMA website</a>)</p>\n\n<h4>Further information:</h4>\n\n<p><a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&amp;mid=WC0b01ac058001d124%5D%20and%20to%20http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000829/WC500130142.pdf\">Information on dabigatran from the European Medicines Agency</a></p>\n\n<p>BNF section 2.8.2 <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.medicinescomplete.com/mc/bnf/current/2791.htm\">Oral anticoagulants</a></p>\n\n<p><em>Article citation: Drug Safety Update July 2012, vol 5 issue 12: A1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-07-01", 
  "date_last_modified": "2013-01-28", 
  "_assets": [], 
  "_item_id": 108, 
  "summary": "Because of the risk of haemorrhage, dabigatran is contraindicated in a range of clinical conditions where the patient is at significant risk of major bleeding (listed in the main article). Dabigatran is also now contraindicated with dronedarone, and with the use of other anticoagulant agents, except when switching therapy to or from dabigatran, or with the use of unfractionated heparin for maintenance of venous or arterial catheter patency.\n\nIn addition, as exposure to dabigatran is substantially increased in patients with renal insufficiency, renal function should be assessed in all patients before starting dabigatran and at least once a year in patients older than 75 years or those with a suspected decline in renal function.", 
  "body": "Article date: July 2012\n\nDabigatran (Pradaxa▼) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation. It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip replacement surgery or total knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day).\n\nHaemorrhage is a common adverse reaction with dabigatran. A review of world-wide data on the risk of bleeding with dabigatran, including results from clinical trials (eg, the [phase III RELY study](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.ncbi.nlm.nih.gov/pubmed/22700854)) and post-marketing surveillance, has resulted in further information and clearer advice  on how best to minimise the risk of bleeding:\n\n### Updated advice on contraindications and warnings:  \n  \n  * Dabigatran is contraindicated in clinical conditions associated with a significant risk of bleeding, such as:   \n    * current or recent gastrointestinal ulceration  \n    * malignant neoplasms  \n    * recent brain or spinal injury  \n    * recent brain, spinal or ophthalmic surgery  \n    * recent intracranial haemorrhage  \n    * oesophageal varices  \n    * arteriovenous malformations  \n    * vascular aneurysms  \n    * major intraspinal or intracerebral vascular abnormalities  \n  * The benefits and risks of starting dabigatran should also be considered carefully for patients who may have other conditions that put them at an increased risk of major bleeding (but in whom treatment with dabigatran is not contraindicated)  \n  * Use of dabigatran is contraindicated with dronedarone, and with other anticoagulants, except when switching treatment to or from dabigatran, or with the use of unfractionated heparin for maintenance of venous or arterial catheter patency  \n  * Concomitant use of antiplatelet agents increases the risk of major bleeding with dabigatran approximately two-fold, therefore a careful benefit-risk assessment should be made prior to initiation of treatment  \n  \n### Advice on switching treatment to and from dabigatran  \n  \n  * When switching to dabigatran, the first dose of dabigatran should be given 0-2 hours prior to the time that the next dose of the alternate medicine is due, or at the time that continuous alternate treatment is discontinued  \n  * When switching from dabigatran to parenteral anticoagulants, an interval of 12-24 hours (dependent upon treatment indication) is recommended between treatments  \n  * When switching from dabigatran to warfarin in patients with atrial fibrillation, the starting time of warfarin should be adjusted according to creatinine clearance (CrCL): CrCL ≥50 ml/min, start warfarin 3 days before discontinuing dabigatran CrCL ≥30 - <50 ml/min, start warfarin 2 days before discontinuing dabigatran  \n  * For patients switching from warfarin to dabigatran, warfarin should be stopped and dabigatran can be given as soon as the INR is <2.0.  \n  \nProduct information will be updated with the new advice.\n\n### Reminder: importance of renal function monitoring  \n  \n  * We previously advised on the importance of renal function monitoring in patients who receive dabigatran, as systemic exposure to dabigatran is substantially increased in patients with renal insufficiency (see [December 2011 Drug Safety Update](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137771))  \n  * Renal function should be assessed in all patients before starting dabigatran and at least once a year in patients older than 75 years or those with a suspected decline in renal function. Dabigatran is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min)  \n  \n### Additional advice and information for healthcare professionals:  \n  \n  * There is no specific antidote to dabigatran and excessive anticoagulation may require interruption of treatment  \n  * In the event of haemorrhagic complications, dabigatran must be discontinued and the source of the bleeding investigated. Adequate diuresis must be maintained, and surgical haemostasis and blood volume replacement should be undertaken at the clinicians’s discretion  \n  \n  * Additional measures may be considered in the treatment of serious haemorrhage, including: activated prothrombin complex concentrates, recombinant factor VIIa, or concentrates of coagulation factors II, IX and X, and platelet concentrates where appropriate. Coagulation tests may become unreliable following administration of reversing agents and measurements may remain elevated despite administration. Caution must be exercised when interpreting these results.  \n  \n  \nA full list of contraindications and warnings, together with updated product information for dabigatran, can be found in the individual Summaries of Product Characteristics (see the [EMA website](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&mid=WC0b01ac058001d124))\n\n#### Further information:\n\n[Information on dabigatran from the European Medicines Agency](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&mid=WC0b01ac058001d124%5D%20and%20to%20http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000829/WC500130142.pdf)\n\nBNF section 2.8.2 [Oral anticoagulants](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.medicinescomplete.com/mc/bnf/current/2791.htm)\n\nArticle citation: Drug Safety Update July 2012, vol 5 issue 12: A1\n"
}